Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The company focuses on reducing attrition in clinical trials and on enhancing drug molecules’ formulation performance through its nanoforming services. Nanoform’s capabilities include GMP manufacturing and span the small to large molecule development space. The company focuses on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications.
Nanoform is an innovative nanoparticle medicine enabling company that supplies unique nanoforming services to enhance biologics and small-molecule APIs. Our multi-patented CESS(R) technology can potentially double the amount of lead compounds progressing into clinic, leading to a significant increase in the number of drugs that reach the market. The green particle engineering process produces pure and stable nanoparticles in some cases as small as 10 nm using supercritical carbon dioxide.
Our work enables our partners to overcome drug development challenges to rapidly progress novel drugs to market, whether biological or small-molecule. We are driven by a passion for innovation, and constantly work to find game-changing solutions that enhance drug effectiveness and targeting.
Our nanoforming services provide solutions to complex formulation challenges by increasing drug solubility and bioavailability. The advanced production of nanoparticles provides pharmacokinetic improvements, commercial opportunities and novel avenues for drug delivery.
We have established a multidisciplinary team that brings together world-class scientists with experts in pharmaceutical business development. Every member of the team is committed to the enhancement of drug compounds for swift progression to the market.
We work with our partners to successfully nanoform small-molecule APIs and biologics for a range of therapeutic areas. Together, we can develop life changing medicines that will reach patients around the globe.
For more information please visit www.nanoform.com
Thanks for sharing, @Quotient_Sci! #ICYMI our first in- human clinical study on nanoformed piroxicam produced additional positive interim results.— Nanoform (@NanoformF) March 4, 2021
We are excited for the future our nanoforming technology can potentially deliver for patients. #smallispowerful https://t.co/7kZhcyYQMT